Literature DB >> 24696709

Experimental study of image-guided percutaneous microwave ablation in rabbit lung VX2 tumor model.

Xin Li1, Weixing Liu2, Haiyan Kou2, Weihua Zhou2, Tao Li2, Baowei Dong3, Ping Liang3.   

Abstract

PURPOSE: To investigate the efficacy and safety of percutaneous microwave ablation.
METHODS: Twenty-six rabbits with lung VX2 tumor were randomly divided into experimental and control group. In the experimental group, microwave ablation guided by ultrasound or CT was performed based on location of the tumor. Enhanced CT scan was carried out immediately before and after the ablation for all animals. Two animals from each group were sacrificed immediately or 1 week after the ablation respectively and the others were followed for the rest of their lives.
RESULTS: CT scan revealed that the tumor was greatly reduced or ablated after ablation. Pathological examination immediately after ablation also confirmed the tumor reduction or ablation. The survival time of the animals in the experimental group was significantly longer than that in the control group.
CONCLUSIONS: Microwave ablation is a safe and effective method for treating lung cancer in rabbits, showing potential clinical applicability.

Entities:  

Keywords:  Microwave ablation; VX2 tumor; lung cancer

Mesh:

Year:  2014        PMID: 24696709      PMCID: PMC3971292     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

Review 1.  Radiofrequency ablation of the liver: current status.

Authors:  J P McGhana; G D Dodd
Journal:  AJR Am J Roentgenol       Date:  2001-01       Impact factor: 3.959

Review 2.  Surgery for early-stage small cell lung cancer.

Authors:  Bryan J Schneider; Ashish Saxena; Robert J Downey
Journal:  J Natl Compr Canc Netw       Date:  2011-10       Impact factor: 11.908

Review 3.  Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough.

Authors:  G D Dodd; M C Soulen; R A Kane; T Livraghi; W R Lees; Y Yamashita; A R Gillams; O I Karahan; H Rhim
Journal:  Radiographics       Date:  2000 Jan-Feb       Impact factor: 5.333

4.  Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report.

Authors:  W A Fry; J L Phillips; H R Menck
Journal:  Cancer       Date:  1999-11-01       Impact factor: 6.860

Review 5.  Tumor ablation with radio-frequency energy.

Authors:  G S Gazelle; S N Goldberg; L Solbiati; T Livraghi
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

6.  Histopathological changes after microwave coagulation therapy for patients with hepatocellular carcinoma: review of 15 explanted livers.

Authors:  Noriyo Yamashiki; Tomoaki Kato; Pablo A Bejarano; Mariana Berho; Berta Montalvo; Robert T Shebert; Zachary D Goodman; Toshihito Seki; Eugene R Schiff; Andreas G Tzakis
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

7.  CT-guided radiofrequency ablation: a potential complementary therapy for patients with unresectable primary lung cancer--a preliminary report of 33 patients.

Authors:  Giuseppe Belfiore; Giovanni Moggio; Enrico Tedeschi; Michele Greco; Riccardo Cioffi; Francesca Cincotti; Renato Rossi
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

Review 8.  Percutaneous ablation of hepatocellular carcinoma: state-of-the-art.

Authors:  Riccardo Lencioni; Dania Cioni; Laura Crocetti; Carlo Bartolozzi
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  Surgical experience in treating T4 lung cancer: its resectability, morbidity, mortality and prognosis.

Authors:  C P Hsu; N Y Hsu; C Y Chen
Journal:  Eur J Surg Oncol       Date:  1996-04       Impact factor: 4.424

10.  Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report.

Authors:  Jeong Min Lee; Gong Yong Jin; S Nahum Goldberg; Yong Cheol Lee; Gyung Ho Chung; Young Min Han; Sang Yong Lee; Chong Soo Kim
Journal:  Radiology       Date:  2003-11-26       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.